Results 131 to 140 of about 140,297 (347)

Resistance to antibody–drug conjugates: A review

Acta Pharmaceutica Sinica B
Antibody-drug conjugates (ADCs) are antitumor drugs composed of monoclonal antibodies and cytotoxic payload covalently coupled by a linker. Currently, 15 ADCs have been clinically approved worldwide. More than 100 clinical trials at different phases are underway to investigate the newly developed ADCs.
Sijia Li, Xinyu Zhao, Kai Fu, Shuangli Zhu, Can Pan, Chuan Yang, Fang Wang, Kenneth K.W. To, Liwu Fu   +8 more
openaire   +3 more sources

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

Targeting CD19 in B-cell lymphoma: emerging role of SAR3419

Cancer Management and Research, 2013
Ali Raufi, Abdul Shukkur Ebrahim, Ayad Al-Katib Lymphoma Research Laboratory, Wayne State University School of Medicine (WSU-SOM), Gordon Scott Hall for Basic Medical Sciences, Detroit, MI, USA Abstract: Non-Hodgkin lymphoma symbolizes a heterogeneous ...
Raufi A, Ebrahim AS, Al-Katib A
doaj  

Modeling antibody drug conjugate potential using a granzyme B antibody fusion protein

BMC Biology
Background Antibody drug conjugates (ADCs) constitute a promising class of targeted anti-tumor therapeutics that harness the selectivity of monoclonal antibodies with the potency of cytotoxic drugs.
Trevor S. Anderson, Amanda L. McCormick, Savanna L. Smith, Devin B. Lowe   +3 more
doaj   +1 more source

Application of a trifunctional reactive linker for the construction of antibody–drug hybrid conjugates [PDF]

, 2008
J Thomas, Thomas Höfer, Christoph Rader, Terrence R. Burke   +3 more
openalex   +1 more source

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

Antibody-Drug Conjugates for the Treatment of Non–Hodgkin's Lymphoma: Target and Linker-Drug Selection [PDF]

, 2009
Andrew G. Polson, Jill Calemine-Fenaux, Pamela Chan, Wesley Chang, Erin Christensen, Suzanna Clark, Frédéric J. de Sauvage, Dan Eaton, Kristi Elkins, J. Michael Elliott, Gretchen Frantz, Reina N. Fuji, Alane Gray, Kristin Harden, Gladys S. Ingle, Noelyn M. Kljavin, Hartmut Koeppen, Christopher A. Nelson, Saileta Prabhu, Helga Raab, Sarajane Ross, Jean-Philippe Stéphan, Suzie J. Scales, Susan D. Spencer, Richard Vandlen, Bernd J. Wranik, Shang‐Fan Yu, Bing Zheng, Allen Ebens   +28 more
openalex   +1 more source

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

Molecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Ezgi June Olgac, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman   +17 more
wiley   +1 more source

Antibody drug-conjugates targeting the tumor vasculature [PDF]

, 2009
Hans‐Peter Gerber, Peter D. Senter, Iqbal S. Grewal   +2 more
openalex   +1 more source

Characterizing epithelial‐mesenchymal transition‐linked heterogeneity in breast cancer circulating tumor cells at a single‐cell level

Molecular Oncology, EarlyView.
In over 50% of non‐metastatic breast cancer patients, circulating tumor cells (CTCs) along the whole epithelial‐mesenchymal transition spectrum are detected. Total CTC number and individual phenotypes relate to aggressive disease characteristics, including lymph node involvement and higher tumor proliferation. At the single‐cell level, mesenchymal CTCs
Justyna Topa, Julia Richert, Tomasz Stokowy, Alicja Staśczak, Mariusz Szajewski, Maciej Ciesielski, Petra M. Grešner, Bartłomiej Tomasik, Łukasz Arcimowicz, Agnieszka Stankiewicz, Grażyna Suchodolska, Elżbieta Senkus, Wiesław Kruszewski, Anna J. Żaczek, Aleksandra Markiewicz   +14 more
wiley   +1 more source